Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide

Malignant gliomas have poor prognosis and urgently require new therapies. Activating Transcription Factor 5 (ATF5) is highly expressed in gliomas, and interference with its expression/function precipitates targeted glioma cell apoptosis in vitro and in vivo. We designed a novel deliverable truncated...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncotarget 2016-03, Vol.7 (11), p.12718-12730
Hauptverfasser:	Cates, Charles C, Arias, Angelo D, Nakayama Wong, Lynn S, Lamé, Michael W, Sidorov, Maxim, Cayanan, Geraldine, Rowland, Douglas J, Fung, Jennifer, Karpel-Massler, Georg, Siegelin, Markus D, Greene, Lloyd A, Angelastro, James M
Format:	Artikel
Sprache:	eng
Schlagworte:	Activating Transcription Factors - antagonists & inhibitors Activating Transcription Factors - pharmacology Animals Antineoplastic Agents - pharmacology Brain Neoplasms Carrier Proteins - pharmacology Cell Line, Tumor Drug Design Glioma Humans Mice Peptides - pharmacology Research Paper Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!